SII plans to start clinical trials of Novavax for children in July
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Wednesday
February 01, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
WEDNESDAY, FEBRUARY 01, 2023
SII plans to start clinical trials of Novavax for children in July

Coronavirus chronicle

Hindustan Times
17 June, 2021, 05:15 pm
Last modified: 17 June, 2021, 05:16 pm

Related News

  • Indian vaccine giant Serum plans African plant in global expansion
  • India's Serum Institute applies for full approval of Covishield vaccine
  • 'Hope to launch Covavax for adults in October, in early 2022 for kids': Adar Poonwalla
  • Covishield okayed by 7 EU Nations, Switzerland, Iceland
  • Can manufacture, supply 90-100 million Covishield doses in June: SII to govt

SII plans to start clinical trials of Novavax for children in July

SII also hopes to introduce Covavax, which is a version of US firm Novavax's Covid-19 vaccine candidate, in India by September

Hindustan Times
17 June, 2021, 05:15 pm
Last modified: 17 June, 2021, 05:16 pm
Employees operate a filling machine inside a lab at the Serum Institute of India, in Pune, India, November 30, 2020. Picture taken November 30, 2020. REUTERS/Francis Mascarenhas/Files
Employees operate a filling machine inside a lab at the Serum Institute of India, in Pune, India, November 30, 2020. Picture taken November 30, 2020. REUTERS/Francis Mascarenhas/Files

The Serum Institute of India (SII) plans to start clinical trials of the Novavax vaccine against Covid-19 for children in July, news agency ANI reported on Thursday citing people familiar with the matter.

SII also hopes to introduce Covavax, which is a version of US firm Novavax's Covid-19 vaccine candidate, in the country by September, ANI also said.

Novavax Inc, which has a vaccine manufacturing agreement with SII, said on Monday its Covid-19 vaccine candidate was highly effective with 90.4 per cent efficacy overall and also showed high efficacy against predominantly circulating variants. The vaccine demonstrated 93 per cent efficacy against predominantly circulating variants of concern and variants of interest, Novavax said.

Novavax said in a statement that the vaccine candidate, 'NVX-CoV2373', demonstrated 100 per cent protection against moderate and severe disease, 90.4 per cent efficacy overall and met the primary endpoint in its PREVENT-19 pivotal Phase 3 trial.

The study enrolled 29,960 participants across 119 sites in the US and Mexico to evaluate efficacy, safety and immunogenicity of the vaccine, it added.

On Tuesday, the Indian government said the efficacy data of Novavax vaccine against Covid-19 is promising and encouraging and its clinical trials are in an advanced stage of completion in India. NITI Aayog member (health) VK Paul said the data available in the public domain also indicates the vaccine is safe and highly effective.

"What we are learning from the available data is that this vaccine is very safe and it is highly effective but what makes this vaccine relevant for today is the fact that this vaccine will be produced in India by Serum Institute," he said during a press conference.

Paul said there is preparatory work already accomplished by the Serum Institute of India and that they are also conducting a bridging trial which is in advanced stages of completion.

"I am also hoping that they will also start trials on children which is of special interest to all of us. The pace of vaccination should see a renewed energy from next week onwards when we will realign our efforts, state efforts and effective scale-up at ground level are expected," he added.

Top News

Serum Institute of India

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Will reform pledges to IMF work this time?
    Will reform pledges to IMF work this time?
  • Infographic: TBS
    How to redirect inward remittances to formal channels
  • Photo: TBS
    By-polls in BNP MPs' vacant seats: Few voters in B'baria polling centres, clash in Chapainawabganj

MOST VIEWED

  • People walk outside wearing masks during the coronavirus disease (COVID-19) pandemic in the Harlem area of the Manhattan borough of New York City, New York, U.S., February 10, 2022. REUTERS/Carlo Allegri
    US to end Covid-19 emergency declarations on 11 May
  • A nurse prepares a shot for Jonathan Halter as the German embassy begins its roll out of BioNTech COVID-19 vaccines for German expatriates at a Beijing United Family hospital in Beijing, China January 5, 2023. REUTERS/Thomas Peter/File Photo
    Covid remains a public health emergency, says WHO
  • FIKE PHOTO: Medical staff moves a patient into a fever clinic at a hospital, as coronavirus disease (COVID-19) outbreaks continue in Shanghai, China, December 19, 2022. REUTERS/Aly Song
    China approves two domestically developed Covid drugs
  • People walk with their luggage at a railway station during the annual Spring Festival travel rush ahead of the Chinese Lunar New Year, as the coronavirus disease (COVID-19) outbreak continues, in Shanghai, China January 16, 2023. REUTERS/Aly Song
    Holiday trips within China surge after lifting of Covid curbs
  • Photo: Collected
    India launches world’s 1st intranasal Covid vaccine
  • A vial of the Pfizer-BioNTech coronavirus disease (COVID-19) booster vaccine targeting BA.4 and BA.5 Omicron sub variants is pictured at Skippack Pharmacy in Schwenksville, Pennsylvania, U.S., September 8, 2022. REUTERS/Hannah Beier
    US CDC still looking at potential stroke risk from Pfizer bivalent Covid shot

Related News

  • Indian vaccine giant Serum plans African plant in global expansion
  • India's Serum Institute applies for full approval of Covishield vaccine
  • 'Hope to launch Covavax for adults in October, in early 2022 for kids': Adar Poonwalla
  • Covishield okayed by 7 EU Nations, Switzerland, Iceland
  • Can manufacture, supply 90-100 million Covishield doses in June: SII to govt

Features

An elderly couple's lonely battle to save Dhaka's trees

An elderly couple's lonely battle to save Dhaka's trees

2h | Panorama
Infographic: TBS

How to redirect inward remittances to formal channels

3h | Panorama
Photo: Bloomberg

How the 'madoffs of Manhattan' can unravel Gautam Adani's empire

2h | Panorama
Photo: Collected

Tips to incorporate sustainable construction

1d | Habitat

More Videos from TBS

Alka Yagnik guinness world record

Alka Yagnik guinness world record

1h | TBS Entertainment
Interest rate should be left to market

Interest rate should be left to market

1h | TBS Round Table
Adani’s shares fell sharply after allegation

Adani’s shares fell sharply after allegation

16h | TBS World
Why Messi was blocked on Instagram?

Why Messi was blocked on Instagram?

15h | TBS SPORTS

Most Read

1
Bapex calls candidates for job test 9 years after advert!
Bangladesh

Bapex calls candidates for job test 9 years after advert!

2
Photo: Collected
Energy

8 Ctg power plants out of production

3
Photo: Saqlain Rizve
Bangladesh

Bangladeshi university students identified as problematic users of Facebook, internet: Study

4
Photo: Collected
Court

Japanese mother gets guardianship of daughters, free to leave country

5
Fund cut as Dhaka's fast-track transit projects on slow spending lane
Infrastructure

Fund cut as Dhaka's fast-track transit projects on slow spending lane

6
The International Monetary Fund (IMF) logo is seen outside the headquarters building in Washington, U.S., September 4, 2018. REUTERS/Yuri Gripas/File Photo
Economy

IMF approves $4.7 billion loan for Bangladesh, calls for ambitious reforms

EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]